| abstract |
The invention relates to compounds of formula (I) wherein R<1>, R<2>, R<4> and R<5> have the meaning given in Claim 1. Said compounds are potent 5-HT2A-antagonists and are suitable for the treatment of psychosis, schizophrenia, depression, neurological disorders, memory disorders, Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease, Huntington's disease, eating disorders, e.g. nervous bulimia and anorexia, and premenstrual syndrome and/or for positively influencing compulsive behaviours (obsessive-compulsive disorder, OCD). |